ReviewCancer immunology, immunotherapy : CII2016
CD57 in human natural killer cells and T-lymphocytes.
Review in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 183 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
183 citing papers in PubMed, 314 citations in OpenAlex.
- Trial
- A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Trial
- Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.Journal for immunotherapy of cancer · 2019Trial
- βBrain, behavior, and immunity · 2018Trial
- Co-inhibitory profile and cytotoxicity of CD57Clinical and experimental immunology · 2018Trial
- Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.Leukemia · 2017Trial
- Immunophenotyping of Cellular Therapy Products Against Oncogenic and Viral Targets.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Circulating immune profiling reveals immune signatures associated with disease stage and outcome in endometrial cancer.The journal of liquid biopsy · 2026Article
- Autologous cytokine-induced NK cells as candidate cellular senolytics: evidence, obstacles, and the experiments still needed.GeroScience · 2026Review
- TCR γδ cell-specific STAT5 gain of function induces a druggable chronic human immune dysregulation.Journal of human immunity · 2026Article
- Single-cell sequencing reveals NK cell dysregulation during chronic HIV infection and identifies transitional NK cell cytotoxicity related to HIV reservoir decay.EBioMedicine · 2026Article
- NK cell dysregulation may potentiate cardiovascular disease in adolescents with perinatally acquired HIV on antiretroviral therapy.Nature communications · 2026Article
- Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration.Cell reports. Medicine · 2026Article
- Heparanase-Loaded CAR T Extracellular Vesicles Remodel the Colorectal Tumour Microenvironment and Boost T Cell Antitumor Immunity.Journal of extracellular vesicles · 2026Article
- Altered NK cell receptor profiles and immune-inflammatory markers in adolescent major depressive disorder: associations with cognitive impairment.BMC psychiatry · 2026Article
- Early peripheral immune signaling precedes tau elevation and blood-brain barrier disruption in Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- Article
- Small particles of Echinococcus granulosus (spegs) and Echinococcus multilocularis (spems) promote follicular T helper cell expansion and are associated with IgE and IgG4 class switching in human lymph nodes.Parasites & vectors · 2026Article
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
123 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally differentiated 'senescent' cells with reduced proliferative capacity and altered functional properties. In this article, we review current understanding of the attributes of CD57-expressing T-cells and NK cells in both health and disease and discuss how this marker can inform researchers about their likely functions in human blood and tissues in vivo. While CD57 expression on human lymphocytes indicates an inability to proliferate, these cells also display high cytotoxic potential, and CD57(pos) NK cells exhibit both memory-like features and potent effector functions. Accordingly, frequencies of CD57-expressing cells in blood and tissues have been correlated with clinical prognosis in chronic infections or various cancers and with human aging. Functional modulation of senescent CD57(pos) T-cells and mature CD57(pos) NK cells may therefore represent innovative strategies for protection against human immunological aging and/or various chronic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.